#NACCT2023 ACMT Pre-Symposium - Promo

#NACCT2023 ACMT Pre-Symposium: Bioethics & Medical Toxicology

Wednesday, September 27, 2023
Fairmont The Queen Elizabeth
Join ACMT at the **2023 North American Congress of Clinical Toxicology (NACCT)** annual toxicology conference at the Fairmont The Queen Elizabeth in Montreal, Canada, from September 27th to October 1st, 2023. We are excited to announce the ACMT Pre-Meeting on Wednesday, September 27th, which will delve into the fascinating intersection of **Bioethics and Medical Toxicology**.

The ACMT Pre-Meeting will feature an outstanding lineup of renowned experts who will explore various ethical aspects of the field through a variety of plenaries, debates, and case-based panel discussions. Prepare to be captivated by thought-provoking explorations of topics such as the **Ethical Impacts of Misinformation and Social Media**, **Ethics of Toxicologic Care**, and **Ethics in Medical Toxicology Research & Teaching**.

Our impressive roster of featured speakers includes **Daniel Blaney Cohen**, JD, a Senior Legislative Attorney from the American Medical Association, as he explores "Harm Reduction Strategies and New Rules for Telemedicine and Medications for SUD." Daniel will shed light on the evolving landscape of telemedicine and the ethical considerations surrounding the use of medications for substance use disorder (SUD). Gain valuable insights into the latest harm reduction strategies and discover how new rules and regulations are shaping the field.

Hear from **Dr. Kevin A. Prohaska**, DO, MPH, an Associate Director and Senior Bioethics Consultant from the Office of Clinical Policy at the Food and Drug Administration (FDA). In his session, "**Approved Use vs. Off Label vs. Off-Off Label: What Does the Patient Need/Deserve to Know When Prescribing Medication?**", Dr. Prohaska will dive into the complex world of medication prescribing. Explore the ethical dimensions of approved use, off-label use, and off-off-label use, and discover what information patients truly need and deserve when it comes to prescribing medication.

Don't miss **Dr. Andrew Ian Stolbach**, a Medical Toxicologist and Emergency Physician from Johns Hopkins University, as he tackles the compelling subject of "**Bioethics in Research: Informed Consent From the Very Sick Patient**." Dr. Stolbach's expertise will provide valuable insights into navigating the complexities of obtaining informed consent in challenging medical scenarios.

Prepare for an engaging debate between **Dr. Stephanie T. Weiss** from the National Institute on Drug Abuse (NIDA), and **Dr. Edward W. Boyer** from Brigham and Women's Hospital. Their session, "**Pay to Play: The Ethics of Paying Addiction and Toxicology Patients to be Research Participants**," will explore the complex ethical dilemmas surrounding compensating patients involved in addiction and toxicology research.

We are also thrilled to present a unique session titled "**ChatGPT vs. the Medical Toxicologists**," where an ACMT member will engage in a real-time debate with an AI
counterpart. Witness the fascinating exchange as the human intellect and artificial intelligence collide on the topic of medical toxicology.

Join us for these sessions and so many more! The ACMT Pre-Meeting at #NACCT2023 promises to be a stimulating event that will broaden your horizons and deepen your understanding of the ethical dimensions in medical toxicology. Join us in Montreal on September 27th and be a part of this remarkable gathering of minds at the forefront of bioethics and medical toxicology. Secure your spot today and prepare for an unforgettable experience!

Learner Objectives

7. Understand the ethical implications of growing trends in technology and the role they play in misinformation in the field of medical toxicology.
8. Examine the challenges and considerations surrounding informed consent from critically ill patients in medical toxicology research.
9. Evaluate the ethical dilemmas related to compensating addiction and toxicology patients participating in research studies.
10. Explore harm reduction strategies and the new rules governing telemedicine and medications for substance use disorder (SUD).
11. Examine the ethical dimensions of prescribing medications, including approved use, off-label use, and off-off-label use, and understand the information patients need and deserve in these scenarios.
12. Expand knowledge on bioethics in the context of toxicologic care, research, publishing and teaching.

These learner objectives aim to provide attendees with a comprehensive understanding of the ethical challenges and considerations in medical toxicology, while also fostering critical thinking, knowledge exchange, and networking opportunities among participants.